Loading...
•
Dec 31, 2023
United Therapeutics Q4 2023 Earnings Report
Reported record revenue for the third straight quarter and second straight year, driven by the Tyvaso business.
Key Takeaways
United Therapeutics reported a record $614.7 million in revenue for Q4 2023, a 25% increase compared to Q4 2022. Net income for the quarter was $217.1 million, up from $132.1 million in the same period last year. The company's growth was primarily driven by its Tyvaso business, with Tyvaso DPI showing significant gains.
Total revenues increased by 25% to $614.7 million compared to Q4 2022.
Net income increased to $217.1 million, compared to $132.1 million for Q4 2022.
Tyvaso revenues grew by 45% to $350.6 million due to increased quantities sold, driven by the commercial launch of Tyvaso DPI.
The first human clinical study of a bioengineered organ, the miroliverELAP, was cleared by the FDA.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.com Forward Guidance
The company anticipates future growth driven by its current commercial operations and pipeline, as well as organ manufacturing programs.
Positive Outlook
- Strong foundation in current commercial business
- Upcoming enrollment milestones for innovative pipeline
- Continued momentum for revolutionary organ manufacturing programs
- First human clinical study of a bioengineered organ cleared by the FDA
- Recent opening of the world's first designated pathogen-free clinical supply facility
Challenges Ahead
- Risks and uncertainties described in periodic reports filed with the SEC
- Potential differences between actual results
- Cautionary statements in periodic reports
- Risk factors set forth in periodic reports
- No obligation to update or revise the information
Revenue & Expenses
Visualization of income flow from segment revenue to net income